Tweet
Influenza Other Respir Viruses
. 2024 Apr;18(4):e13292.
doi: 10.1111/irv.13292. Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study
Susana Monge 1 2 , James Humphreys 3 , Nathalie Nicolay 4 , Toon Braeye 5 , Izaak Van Evercooren 5 , Christian Holm Hansen 6 , Hanne-Dorthe Emborg 6 , Chiara Sacco 7 8 , Alberto Mateo-Urdiales 7 , Jesús Castilla 9 10 , Iván Martínez-Baz 9 10 , Brechje de Gier 11 , Susan Hahné 11 , Hinta Meijerink 12 , Anja Bråthen Kristoffersen 12 , Ausenda Machado 13 , Patricia Soares 13 , Anthony Nardone 3 , Sabrina Bacci 4 , Esther Kissling 3 , Baltazar Nunes 3 ; VEBIS‐EHR Working Group
Affiliations
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.
Keywords: COVID‐19; SARS‐CoV‐2; cohort design; electronic health records; hospitalisation; multicountry study; vaccine effectiveness.
. 2024 Apr;18(4):e13292.
doi: 10.1111/irv.13292. Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study
Susana Monge 1 2 , James Humphreys 3 , Nathalie Nicolay 4 , Toon Braeye 5 , Izaak Van Evercooren 5 , Christian Holm Hansen 6 , Hanne-Dorthe Emborg 6 , Chiara Sacco 7 8 , Alberto Mateo-Urdiales 7 , Jesús Castilla 9 10 , Iván Martínez-Baz 9 10 , Brechje de Gier 11 , Susan Hahné 11 , Hinta Meijerink 12 , Anja Bråthen Kristoffersen 12 , Ausenda Machado 13 , Patricia Soares 13 , Anthony Nardone 3 , Sabrina Bacci 4 , Esther Kissling 3 , Baltazar Nunes 3 ; VEBIS‐EHR Working Group
Affiliations
- PMID: 38654485
- DOI: 10.1111/irv.13292
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.
Keywords: COVID‐19; SARS‐CoV‐2; cohort design; electronic health records; hospitalisation; multicountry study; vaccine effectiveness.